Skip to main
LNTH

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings is a radiopharmaceutical-focused company with a promising future due to its strong product lineup and potential growth opportunities in the Alzheimer's diagnostic market. The company has a diversified revenue base with products in multiple categories, and it is expected to benefit from an increase in healthcare professionals' adoption of its products. The recent approval of TruVu and the upcoming PDUFA dates for two of its key products, LNTH-501 and MK6240, could further drive its growth. With the CEO transition on the horizon and potential contributions from royalty opportunities, Lantheus is positioned for success in the coming years.

Bears say

Lantheus Holdings is heavily reliant on two products, PYLARIFY and DEFINITY, for a majority of its revenue, making the company vulnerable to disruptions in either platform from competition or regulatory changes. Additionally, the company's dependence on external manufacturers and third-party payors for reimbursement creates further risks to the business. With PYLARIFY's launch of TruVu in 4Q26 expecting to secure new Transitional Pass Through (TPT) status in 2027, any delays or challenges in rolling out the new formulation could hinder future revenue growth and undermine the company's long-term growth plans.

Lantheus Holdings (LNTH) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 7 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of May 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.